Search Results
Your search for A matches 33002 pages
Showing 4801 - 4850Combination of Botensilimab and Balstilimab Shows Activity in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
A combination of the next-generation immunotherapies botensilimab and balstilimab showed clinical activity in treating patients with refractory metastatic microsatellite-stable (MSS) colorectal cancer, according to new findings presented by El-Khoueiry et al at the 2023 ASCO Gastrointestinal...
Addition of Veliparib to Cisplatin in Advanced Triple-Negative Breast Cancer With BRCA-Like and Non–BRCA-Like Phenotype
In a phase II trial (S1416) reported in The Lancet Oncology, Rodler et al found that the addition of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib to cisplatin significantly improved progression-free survival in patients with germline BRCA1/2 wild-type advanced triple-negative breast...
Ibrutinib in the First-Line Treatment of Chronic GVHD
As reported in the Journal of Clinical Oncology by Miklos et al, the phase III iNTEGRATE trial showed no benefit of the addition of ibrutinib to prednisone in the first-line treatment of moderate or severe chronic graft-vs-host disease (GVHD) after allogeneic hematopoietic cell transplantation....
Accelerated Partial-Breast Irradiation vs Whole-Breast Irradiation: Long-Term Cosmetic Results and Toxicity
As reported in the Journal of Clinical Oncology by Meduri et al, a 5-year analysis from the phase III IRMA trial has shown higher rates of adverse cosmesis and some late toxicities with external-beam accelerated partial-breast irradiation (APBI) vs whole-breast irradiation (WBI) in women with stage ...
Lenvatinib and Pembrolizumab in Previously Treated Patients With Advanced Endometrial Carcinoma: Update of Study 111/KEYNOTE-146
In an analysis reported in the Journal of Clinical Oncology, Vicky Makker, MD, and colleagues provided updated findings from the phase Ib/II Study 111/KEYNOTE-146 trial of lenvatinib and pembrolizumab in previously treated patients with advanced endometrial carcinoma. The study supported the...
Robin Zon Elected ASCO President for 2024–2025 Term; Other Leadership Positions Filled
ASCO has elected Robin Zon, MD, FACP, FASCO, a long-time member and volunteer, as its President beginning in June 2024. Dr. Zon will take office as President-Elect immediately following the ASCO Annual Business Meeting in Chicago on June 5, 2023. Five additional members were elected to the ASCO...
Former ASCO President Monica Bertagnolli Welcomed as NCI Director in Capitol Hill Reception
On December 7, 2022, Association for Clinical Oncology (ASCO) Chief Medical Officer and Executive Vice President Julie Gralow MD, FACP, FASCO, attended a reception on Capitol Hill hosted by the One Voice Against Cancer Coalition and the House Cancer Caucus, to welcome former ASCO President Monica...
ASCO Guideline Offers Recommendations on Prescribing Opioids to Patients With Cancer
A new ASCO guideline on opioids in managing pain from cancer or cancer treatment in adults provides recommendations on administering them in the midst of interventions to address the public health crisis from their misuse and related deaths across the country.1 “ASCO took wonderful leadership in...
Northwell Cancer Institute Welcomes New Chief of Hematologic Malignancies
Northwell Health recently appointed Douglas Gladstone, MD, a leader in hematology and medical oncology, as Chief of Hematologic Malignancies at the Northwell Health Cancer Institute. Prior to joining Northwell, Dr. Gladstone served for 14 years as Clinical Director of the outpatient bone marrow...
Expert Point of View: Solange Peters, MD, PhD
The formal discussant of ARC-7 was Solange Peters, MD, PhD, Chair of Medical Oncology, Centre D’Oncologie Chuv, Lausanne University Hospital, Switzerland, and President of the European Society for Medical Oncology. Dr. Peters described how TIGIT (T-cell immunoglobulin and ITIM domain) plays a role ...
Anti-TIGIT Antibody May Boost the Benefit of Immunotherapy in Stage IV Lung Cancer
In a phase II study of stage IV non–small cell lung cancer (NSCLC), domvanalimab, a novel antibody that blocks T-cell immunoglobulin and ITIM domain (TIGIT), when added to anti–PD-1 zimberelimab immunotherapy resulted in improved response rates and progression-free survival compared with...
Yale Cancer Center Presents 2022 Research Awards
Yale Cancer Center’s Annual Conclave, held on January 5, recognized the scientific and clinical accomplishments of the Center’s faculty and staff in 2022. Eric Winer, MD, hosted the event and presented research awards in four categories: The Yale Cancer Center Population Science Research Prizes...
Olutasidenib for Relapsed or Refractory Acute Myeloid Leukemia With a Susceptible IDH1 Mutation
On December 1, 2022, the IDH1 inhibitor olutasidenib was approved for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation, as detected by a U.S. Food and Drug Administration (FDA)-approved test.1 The FDA simultaneously approved the Abbott...
Expert Point of View: Jane N. Winter, MD and Catherine Bollard, MBChB, MD
Offering their thoughts on the study by Williams et al from the St. Jude Lifetime Cohort were Jane N. Winter, MD, Immediate Past President of the American Society of Hematology (ASH), and Catherine Bollard, MBChB, MD. Both moderated press briefings where the results were presented or discussed....
Many Survivors of Childhood Hodgkin Lymphoma Show Signs of Neurocognitive Impairment
Long-term follow-up of survivors of childhood Hodgkin lymphoma from the St. Jude Lifetime Cohort showed signs of “epigenetic accelerated aging,” and many of these survivors had signs of neurocognitive impairment by their late 30s, researchers reported at the 2022 American Society of Hematology...
Expert Point of View: Julio Chavez, MD
Julio Chavez, MD, a hematologist at Moffitt Cancer Center, Tampa, Florida, commented on the updated results from the MAGNOLIA trial. “MAGNOLIA was a phase II trial that included patients with marginal zone lymphoma after one or more prior lines of therapy. At the ASH meeting, we heard updated...
MAGNOLIA Trial: Zanubrutinib Yields High Response Rates With Low Rate of Cardiac Events in Marginal Zone Lymphoma
Zanubrutinib—a next-generation Bruton’s tyrosine kinase (BTK) inhibitor—achieved high response rates and durable disease control with a low incidence of cardiac effects in patients with relapsed or refractory marginal zone lymphoma, according to updated findings from the final analysis of the phase ...
Subset of Patients With Advanced Gastric/GEJ Cancer May Benefit From CLDN18.2-Targeted Drug Zolbetuximab: SPOTLIGHT Study
Initial data from the global phase III SPOTLIGHT trial could herald the use of a new targeted agent for a subset of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. First-line treatment with zolbetuximab, which targets the transmembrane protein claudin 18.2...
Is the Risk of Suicide Higher Among Individuals With Cancer?
According to a large new study led by researchers at the American Cancer Society, the risk of suicide for individuals diagnosed with cancer in the United States is 26% higher compared with the general population. Geographic, racial/ethnic, socioeconomic, and clinical characteristics contributed to...
First-Line Zanidatamab Plus Chemotherapy for HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
Tolerability and efficacy results—including the first overall survival data—from a phase II trial examining first-line zanidatamab, an investigational HER2-targeted bispecific antibody, in combination with chemotherapy for patients with HER2-expressing metastatic gastroesophageal adenocarcinoma...
Futibatinib in Previously Treated Patients With Advanced FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
In a phase II study (FOENIX-CCA2) published in The New England Journal of Medicine, Lipika Goyal, MD, and colleagues found that the next-generation, covalently binding FGFR1-4 inhibitor futibatinib showed activity in previously treated patients with unresectable or metastatic FGFR2-altered...
Expert Point of View: Alexey Danilov, MD
Alexey Danilov, MD, PhD, Co-Director, Toni Stephenson Lymphoma Center and Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, commented on the phase III ALPINE trial comparing ibrutinib and zanubrutinib in patients...
FDA Approves Zanubrutinib for CLL or SLL
On January 19, the U.S. Food and Drug Administration (FDA) approved the kinase inhibitor zanubrutinib (Brukinsa) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). SEQUOIA Trial: Treatment-Naive Patients Efficacy in treatment-naive patients...
Is Zanubrutinib Poised to Become a New Standard of Care in Relapsed or Refractory CLL and SLL?
The next-generation Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib demonstrated superior progression-free survival compared with ibrutinib, with an improved cardiac safety profile, in the first head-to-head comparison between these two BTK inhibitors in relapsed or refractory chronic...
Expert Point of View: Bita Fakhri, MD, MPH
Moderator of the session on the CLL2-GIVe regimen, Bita Fakhri, MD, MPH, Assistant Professor of Medicine at Stanford Medicine, California, said that findings from the ongoing, phase III CLL13 trial will ultimately determine which regimen is appropriate for patients with high-risk chronic...
CLL2-GIVe Trial: Regimen of Obinutuzumab, Ibrutinib, and Venetoclax Effective in High-Risk CLL
The first-line combination of obinutuzumab, ibrutinib, and venetoclax appears to be effective in treating high-risk chronic lymphocytic leukemia (CLL), according to data presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.1 Results of the CLL2-GIVe trial, which...
FDA Grants Accelerated Approval to Tucatinib Plus Trastuzumab for Advanced HER2-Positive Colorectal Cancer
On January 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the kinase inhibitor tucatinib (Tukysa) in combination with the monoclonal antibody trastuzumab for RAS wild-type, HER2-positive, unresectable or metastatic colorectal cancer that has progressed following...
Expert Point of View: Mrinal S. Patnaik, MBBS
Mrinal S. Patnaik, MBBS, Chair of the Acute Leukemia and Myeloid Neoplasms Group and Scientific Director of the Epigenetics Developmental Laboratory and the Epigenomics Program at the Mayo Clinic, Rochester, Minnesota, offered his thoughts on the phase II study findings of ruxolitinib’s efficacy...
Tremelimumab-actl in Combination With Durvalumab for Unresectable Hepatocellular Carcinoma
On October 21, 2022, tremelimu-mab-actl was approved by the U.S. Food and Drug Administration (FDA) for use in combination with durvalumab in the treatment of unresectable hepatocellular carcinoma.1 Supporting Efficacy Data Approval was based on a comparison of overall survival in the...
Expert Point of View: Mikkael Sekeres, MD
“Standard treatment of older or less fit adults with acute myeloid leukemia (AML) is now venetoclax/azacitidine, which has been shown to improve overall survival vs azacitidine monotherapy. Since that backbone was established, there has been a tsunami of trials looking at drugs added to this...
Studies Explore Novel Triplet Combinations in AML
Two separate studies presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition provide preliminary evidence that triplet combinations may have a role in the treatment of acute myeloid leukemia (AML). Both triplets were based on the addition of a third drug to standard ...
Expert Point of View: Neil J. Shah, MBBS
Neil J. Shah, MBBS, a medical oncologist at Memorial Sloan Kettering Cancer Center, New York, called the cohort study “one of a kind” because of the ability to match baseline cohorts of people living with and without HIV and metastatic non–small cell lung cancer. “These findings should be very...
Study Finds Immune Checkpoint Inhibitors Safe and Effective for Patients Living With HIV Who Have NSCLC
Immune checkpoint inhibitors are safe and effective for people living with HIV who have metastatic non–small cell lung cancer (NSCLC), according to data presented at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.1 Findings from the first matched cohort to compare clinical...
Expert Point of View: Renata Ferrarotto, MD
Renata Ferrarotto, MD, Associate Professor, and Director of Head and Neck Clinical Research at The University of Texas MD Anderson Cancer Center, Houston, called the efficacy results with cabozantinib plus atezolizumab in recurrent or metastatic head and neck squamous cell carcinoma “encouraging”...
Cabozantinib Plus Atezolizumab Warrants Further Study in Treatment of Advanced Head and Neck Cancer
A challenging patient population with advanced head and neck cancer may have a new treatment option, according to data presented during the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.1 Results from Cohort 17 of the COSMIC-021 study showed that the combination of the kinase...
Expert Point of View: Ajay K. Nooka, MD, MPH
Insights on findings from the phase II MonumenTAL-1 trial1 were offered by Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology, and Medical Director of the Winship Data and Technology Applications Shared Resource, Winship Cancer Institute, Emory University School ...
ASH 2022: Multiple Myeloma Highlights
The 2022 American Society of Hematology (ASH) Annual Meeting and Exposition was full of interesting abstracts in multiple myeloma. In addition to full coverage of several important presentations, The ASCO Post offers readers quick takes on some studies that could be practice-changing and others...
Expert Point of View: Debu Tripathy, MD
Debu Tripathy, MD, Professor of Medicine and Chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, said that the study points the way to further exploration of the benefit of adding immunotherapy to treatment after patients develop resistance to CDK4/6 inhibitors for ...
Palbociclib/Fulvestrant Does Not Improve Progression-Free Survival After Progression on a CDK4/6 Inhibitor in Metastatic Breast Cancer
The combination of palbociclib and fulvestrant did not prolong progression-free survival compared to fulvestrant alone in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who had disease progression on prior treatment with a CDK4/6 inhibitor and endocrine therapy,...
Expert Point of View: Virginia Kaklamani, MD
Breast medical oncologist Virginia Kaklamani, MD, Professor of Medicine, UT Health San Antonio, MD Anderson Cancer Center, believes the results of the POSITIVE trial will help patients with breast cancer make decisions. “The trial is important because it helps us give advice to younger patients,”...
Can Younger Women With Hormone Receptor–Positive Breast Cancer Safely Pause Endocrine Therapy to Pursue Pregnancy?
Preserving fertility is a driving concern for many young women with breast cancer. Many of these women have hormone receptor–positive breast cancer and are treated with adjuvant endocrine therapy for 5 to 10 years, which is known to compromise fertility. Younger women who may want to take a break...
Expert Point of View: Carlos L. Arteaga, MD and William Sikov, MD
“There is a clear suggestion from SERENA-2 that camizestrant might be a better treatment than fulvestrant,” said press briefing moderator Carlos L. Arteaga, MD, Director of the Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center, Dallas. “As ...
SERENA-2 Trial: Camizestrant Improves Progression-Free Survival in Advanced Breast Cancer
The oral selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, as compared with fulvestrant, in previously treated postmenopausal women with advanced breast cancer in the phase II SERENA-2 trial. These results were reported at the 2022 San Antonio Breast...
Expert Point of View: Jason Aboudi Mouabbi, MD
“These results [from the TRIO-US B-12 TALENT trial] are exciting and impressive in HER2-low, hormone receptor–positive patients. The authors were testing the waters and got a positive signal,” said Jason Aboudi Mouabbi, MD, a medical oncologist at MD Anderson Cancer Center, Houston. “The beauty of ...
Neoadjuvant T-DXd Demonstrates Activity in Phase II Study of Patients With HER2-Low Breast Cancer
A pilot study provides a signal that the novel HER2 antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd), is active in the neoadjuvant setting in patients with HER2-low breast cancer. Overall response rates were 75% with T-DXd alone and 63% when T-DXd was combined with endocrine therapy...
Expert Point of View: Virginia Kaklamani, MD
Virginia Kaklamani, MD, Professor of Medicine at the University of Texas (UT) Health Science Center San Antonio and leader of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center, was enthusiastic about the results of the phase III CAPItello-291 trial. “The phase III...
Capivasertib Plus Fulvestrant Doubles Progression-Free Survival in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
The combination of capivasertib, an AKT pathway inhibitor, plus fulvestrant, an estrogen receptor antagonist, significantly improved progression-free survival compared with fulvestrant alone in patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to results of...
Addressing the Continued Existence of Racial Inequities in Cancer Care
The opportunity to write this commentary on cancer disparities comes at a sorrowful time for me. Despite practicing as a surgical oncologist for more than 20 years and understanding the unequal burden that cancer visits on the Black community, I was woefully unprepared for the premature death of my ...
Study Reports Activity With Oncolytic Vaccine Plus Pembrolizumab in BCG-Unresponsive Bladder Cancer
An oncolytic therapy delivered within the urinary bladder in combination with pembrolizumab has yielded high complete response rates in patients with bacillus Calmette-Guérin (BCG)-unresponsive bladder cancer, according to data presented by Roger Li, MD, lead study investigator and urologic...
Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma
In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...
